CoTherix’ Ventavis Cleared For Combination Use
This article was originally published in The Pink Sheet Daily
Executive Summary
Ventavis’ expanded label addresses use of the inhaled pulmonary arterial hypertension therapy in combination with Actelion’s oral Tracleer.
You may also be interested in...
Actelion Acquires CoTherix For $420 mil.
Swiss firm projects that sales of its newly acquired product Ventavis could add roughly $100 mil. in 2007 revenue.
Actelion Acquires CoTherix For $420 mil.
Swiss firm projects that sales of its newly acquired product Ventavis could add roughly $100 mil. in 2007 revenue.
Ventavis To Cost $65,000 - $100,000 Per Year, CoTherix Says
The PAH therapy is competitively priced against United Therapeutics' Remodulin and Actelion's Tracleer, CoTherix says. With its sales force still in training, Ventavis has launched ahead of schedule.